The latest price target for Nuvation Bio (NYSE:NUVB) was reported by HC Wainwright & Co. on January 23, 2025. The analyst firm set a price target for $11.00 expecting NUVB to rise to within 12 months (a possible 384.58% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Nuvation Bio (NYSE:NUVB) was provided by HC Wainwright & Co., and Nuvation Bio maintained their buy rating.

The last upgrade for Nuvation Bio Inc happened on March 27, 2024 when Jefferies raised their price target to $10. Jefferies previously had a hold for Nuvation Bio Inc.

The last downgrade for Nuvation Bio Inc happened on January 6, 2023 when Jefferies changed their price target from $5 to $2 for Nuvation Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvation Bio was filed on January 23, 2025 so you should expect the next rating to be made available sometime around January 23, 2026.

While ratings are subjective and will change, the latest Nuvation Bio (NUVB) rating was a maintained with a price target of $10.00 to $11.00. The current price Nuvation Bio (NUVB) is trading at is $2.27, which is out of the analyst’s predicted range.